29C1 Stock Chart & Stats
€1.93
€0.08(3.85%)
At close: 4:00 PM EDT
€1.93
€0.08(3.85%)
Day’s Range― - ―
52-Week Range€1.89 - €2.46
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€126.14M
Enterprise Value€291.62
Total Cash (Recent Filing)€10.05M
Total Debt (Recent Filing)€76.33M
Price to Earnings (P/E)7.6
Beta0.17
Next Earnings
Nov 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding63,514,038
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.19
Price to Sales (P/S)0.65
P/FCF Ratio10.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.96Price Target Upside53.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.09
Revenue Forecast (FY)€238.23M
Bulls Say, Bears Say
Bulls Say
Profitability And Cash GenerationThe return to profitability is supported by meaningful operating and free cash flow, rather than earnings alone. Free cash flow equal to about 84% of net income and 120% TTM growth provide funding for dividends, debt service, and continued investment in the operating platform.
Long-term Contract And Bed GrowthThe long-term national contract expands CareRx’s recurring institutional service base and increases prescription volume tied to retirement-home occupancy. Its scale should improve network utilization and supports durable revenue and EBITDA growth as onboarding is completed and benefits mature.
Improved Balance-sheet LeverageLower leverage materially improves financial flexibility compared with earlier periods and reduces the balance-sheet burden carried by the business. Combined with positive profitability and cash generation, the improvement strengthens CareRx’s capacity to fund growth while managing debt obligations.
Bears Say
Thin Operating MarginsAlthough CareRx is profitable, its modest EBIT and EBITDA margins leave earnings sensitive to cost increases, funding changes, or weaker volume growth. Limited operating leverage means incremental revenue may not translate proportionally into profit, constraining resilience over the next several quarters.
Ontario Funding HeadwindThe funding change creates a multi-period revenue and earnings headwind rather than a one-quarter variance. Recovery depends on ward-bed redevelopment and is not expected until late 2027, leaving CareRx exposed to a prolonged reduction in revenue from affected beds.
Lower Liquidity And Higher Net DebtThe simultaneous decline in cash and increase in net debt reduces near-term financial flexibility, particularly while margins remain thin. Although leverage is still moderate, less liquidity leaves fewer resources to absorb operating volatility, fund capital needs, or pursue expansion without additional borrowing.
CareRx News
29C1 FAQ
What was CareRx’s price range in the past 12 months?
CareRx lowest stock price was €1.89 and its highest was €2.46 in the past 12 months.
What is CareRx’s market cap?
CareRx’s market cap is €126.14M.
When is CareRx’s upcoming earnings report date?
CareRx’s upcoming earnings report date is Nov 11, 2026 which is in 57 days.
How were CareRx’s earnings last quarter?
CareRx released its earnings results on Jul 29, 2026. The company reported €0.006 earnings per share for the quarter, missing the consensus estimate of €0.014 by -€0.008.
Is CareRx overvalued?
According to Wall Street analysts CareRx’s price is currently Undervalued.
Does CareRx pay dividends?
CareRx does not currently pay dividends.
What is CareRx’s EPS estimate?
CareRx’s EPS estimate is 0.02.
How many shares outstanding does CareRx have?
CareRx has 63,514,038 shares outstanding.
What happened to CareRx’s price movement after its last earnings report?
CareRx reported an EPS of €0.006 in its last earnings report, missing expectations of €0.014. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CareRx?
Currently, no hedge funds are holding shares in DE:29C1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€2.96 (53.15% Upside)
€2.96 (53.15% Upside)
Insider Transactions
Bought Shares
Worth €19.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.82%
12-Months-Change
Fundamentals
Return on Equity
2.50%
Trailing 12-Months
Asset Growth
11.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CareRx
CareRx Corporation, operating with its subsidiaries, specializes in delivering tailored pharmaceutical services to Canada's senior demographic. The company manages a vast network of medication dispensing facilities, which are responsible for providing chronic prescriptions and a variety of other advanced clinical pharmacy solutions. Currently, it caters to approximately 50,000 individuals residing in roughly 900 distinct senior and communal living environments, including extended care residences, retirement communities, supportive living facilities, and group homes. Founded in 2001 and based in Toronto, Canada, the corporation rebranded as CareRx Corporation in June 2020, having formerly been known as Centric Health Corporation.
29C1 Stock 12 Month Forecast
Average Price Target
€2.96
▲(53.15% Upside)
Technical Analysis
Extendicare
―
Nova Leap Health
―
Sienna Senior Living
―
Medical Facilities
―
WELL Health Technologies Corp
―